Key Takeaways
- Eli Lilly (LLY) reports Foundayo reduced the risk of MACE-4 events by 16% and slashed the risk of all-cause death by 57% compared to insulin glargine.
- BNY Mellon (BK) authorized a massive $10 billion share repurchase program and declared a $0.53 per share quarterly dividend.
- The International Energy Agency (IEA) warns Europe has approximately six weeks of jet fuel remaining as the Iran war blocks vital supply routes.
- Syrian forces have officially taken control of the Qasrak Air Base, marking the final withdrawal of the U.S.-led International Coalition from the country.
- Eli Lilly plans to submit Foundayo for Type 2 diabetes treatment to the FDA by the end of Q2 2026 following successful ACHIEVE-4 trial results.
Eli Lilly’s Foundayo Hits Major Clinical Milestones
Eli Lilly and Company (LLY) announced groundbreaking results from its Phase 3 ACHIEVE-4 trial, demonstrating that its oral GLP-1 drug Foundayo (orforglipron) significantly improves cardiovascular outcomes. The trial showed a 16% reduction in MACE-4 events (major adverse cardiovascular events) and a staggering 57% lower risk of all-cause death compared to insulin glargine.
The company confirmed that Foundayo also provided superior results in secondary health measures, including cholesterol and blood pressure levels. Analysts suggest these results could position Foundayo as a dominant player in the cardiometabolic market, especially as the company prepares to submit the drug for Type 2 diabetes approval to the FDA by the end of Q2 2026.
Safety and tolerability in the ACHIEVE-4 trial were reported as similar to prior trials and consistent with the broader GLP-1 class. This data is expected to address previous FDA inquiries regarding the drug's long-term cardiovascular and liver safety profile following its initial weight-loss approval earlier this month.
BNY Mellon Announces $10B Buyback and Record Earnings
The Board of Directors at BNY Mellon (BK) has authorized a new $10 billion share repurchase program, signaling strong confidence in the bank's capital position. Alongside the buyback, the board declared a quarterly common stock dividend of $0.53 per share, payable on May 8, 2026, to shareholders of record as of April 27.
The capital return program follows a robust Q1 2026 earnings report, where the bank posted record revenue of $5.41 billion, a 13% increase year-over-year. Net income surged to $1.63 billion, resulting in earnings per share of $2.24, which comfortably beat the consensus estimate of $1.92.
CEO Robin Vince highlighted that the results reflect broad-based growth across Securities Services and Market and Wealth Services. The bank's strongest quarterly sales performance in history has driven the stock higher in pre-market trading as investors react to the aggressive buyback and earnings beat.
Global Energy Crisis and Geopolitical Shifts
International Energy Agency (IEA) Executive Director Fatih Birol issued a dire warning today, stating that Europe may have only six weeks of jet fuel left. The shortage is a direct consequence of the Iran war, which has blocked oil and gas supplies through the Strait of Hormuz, creating what Birol described as "the largest energy crisis we have ever faced."
Market participants are bracing for potential flight cancellations and significant inflationary pressure across the Eurozone if the blockade continues. The IEA noted that while the U.S. has increased exports to help, it only covers roughly 50% of the lost Middle Eastern supply, leaving European inventories at critical levels.
In a separate geopolitical development, the Syrian Ministry of Defense announced that the Syrian Army's 60th Division has taken control of the Qasrak Air Base. This move follows the complete withdrawal of International Coalition forces, marking the end of the U.S. military presence in Syria. The handover is seen as a historic shift in regional sovereignty and the culmination of a withdrawal process that began in early 2026.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.